Advertisement

Endocrine Pathology

, Volume 28, Issue 2, pp 159–164 | Cite as

Malignancy in Pheochromocytoma or Paraganglioma: Integrative Analysis of 176 Cases in TCGA

  • Yong Joon Suh
  • Ji-Young Choe
  • Hyo Jin Park
Article

Abstract

Methods of diagnosing malignant pheochromocytoma (PCC) or paraganglioma (PGL) are needed. However, there are no reliable histopathologic criteria to distinguish malignant PCC/PGLs. The recent genomic analysis of The Cancer Genome Atlas (TCGA) provides in-depth information enabling more accurate diagnosis of disease entities. Therefore, we investigated genomic expression differences and mutational differences of malignant PCC/PGLs with TCGA. As of December 2014, TCGA had acquired multigenomic analysis of 176 PCC/PGL samples. Clinical information, mutation status, and 20,531 gene messenger RNA (mRNA) expression dataset of normalized RNA-sequencing mRNA read counts were downloaded from TCGA, and integrated into a table. Of the 176 PCC/PGL samples in the dataset, 14 had metastasis and 162 exhibited no metastasis. mRNA expression and mutations were compared in these two groups. There were 76 males in the dataset of 176 TCGA samples. Mean age was 47.6 ± 15.2 years (19–83 years). There was no significant gender or race difference between metastatic and non-metastatic groups. mRNA expression of malignant PCC/PGLs was upregulated in five pathways of cell cycle (BUB1, BUB1B, CCNB2, CDC2, ESPL1), calcium signaling (CCNB2, CDC2, PRKCB1), regulation of actin cytoskeleton (DIAPH3, FGF18, IQGAP3), gap junction (CDC2, PRKCB1), and phosphatidylinositol (PRKCB1, TTK). Disease-free survival rates were significantly correlated with the presence or absence of mutations, such as RP11-798G7.5, HERC2, SETD2, TGDS, TRHDE, FKBP9, and BMS1. TCGA showed differences in mRNA expression and mutations between metastatic and non-metastatic PCC/PGLs. The improved recognition of genetic causes can help to achieve proper diagnosis and provide appropriate treatment of PCC/PGL.

Keywords

Pheochromocytoma Paraganglioma Malignancy TCGA 

Notes

Acknowledgements

The results shown here were in part based upon the data generated by TCGA Research Network.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Supplementary material

12022_2017_9479_MOESM1_ESM.docx (22 kb)
ESM 1 (DOCX 22 kb).

References

  1. 1.
    Lenders JW, Eisenhofer G, Mannelli M, Pacak K: Phaeochromocytoma. Lancet 366: 665–675, 2005CrossRefPubMedGoogle Scholar
  2. 2.
    Corssmit EP, Romijn JA: Clinical management of paragangliomas. Eur J Endocrinol 171: R231–R243, 2014CrossRefPubMedGoogle Scholar
  3. 3.
    Kiernan CM, Solorzano CC: Pheochromocytoma and paraganglioma: diagnosis, genetics, and treatment. Surg Oncol Clin N Am 25: 119–138, 2016CrossRefPubMedGoogle Scholar
  4. 4.
    Joynt KE, Moslehi JJ, Baughman KL: Paragangliomas: etiology, presentation, and management. Cardiol Rev 17: 159–164, 2009CrossRefPubMedGoogle Scholar
  5. 5.
    Bravo EL, Tagle R: Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev 24: 539–553, 2003CrossRefPubMedGoogle Scholar
  6. 6.
    Lenders JW, Duh QY, Eisenhofer G, et al.: Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99: 1915–1942, 2014CrossRefPubMedGoogle Scholar
  7. 7.
    Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB: The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 14: 569–585, 2007CrossRefPubMedGoogle Scholar
  8. 8.
    Baudin E, Habra MA, Deschamps F, et al.: Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. Eur J Endocrinol 171: R111–R122, 2014CrossRefPubMedGoogle Scholar
  9. 9.
    Adjalle R, Plouin PF, Pacak K, Lehnert H: Treatment of malignant pheochromocytoma. Horm Metab Res 41: 687–696, 2009CrossRefPubMedGoogle Scholar
  10. 10.
    Tischler AS, Pacak K, Eisenhofer G: The adrenal medulla and extra-adrenal paraganglia: then and now. Endocr Pathol 25: 49–58, 2014CrossRefPubMedGoogle Scholar
  11. 11.
    Elder EE, Elder G, Larsson C: Pheochromocytoma and functional paraganglioma syndrome: no longer the 10% tumor. J Surg Oncol 89: 193–201, 2005CrossRefPubMedGoogle Scholar
  12. 12.
    Andersen KF, Altaf R, Krarup-Hansen A, et al.: Malignant pheochromocytomas and paragangliomas—the importance of a multidisciplinary approach. Cancer Treat Rev 37: 111–119, 2011CrossRefPubMedGoogle Scholar
  13. 13.
    Thompson LD: Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 26: 551–566, 2002CrossRefPubMedGoogle Scholar
  14. 14.
    Goffredo P, Sosa JA, Roman SA: Malignant pheochromocytoma and paraganglioma: a population level analysis of long-term survival over two decades. J Surg Oncol 107: 659–664, 2013CrossRefPubMedGoogle Scholar
  15. 15.
    Gimm O, DeMicco C, Perren A, Giammarile F, Walz MK, Brunaud L: Malignant pheochromocytomas and paragangliomas: a diagnostic challenge. Langenbecks Arch Surg 397: 155–177, 2012CrossRefPubMedGoogle Scholar
  16. 16.
    de Krijger RR, van Nederveen FH, Korpershoek E, Dinjens WN: New developments in the detection of the clinical behavior of pheochromocytomas and paragangliomas. Endocr Pathol 17: 137–141, 2006CrossRefPubMedGoogle Scholar
  17. 17.
    Scholz T, Schulz C, Klose S, Lehnert H: Diagnostic management of benign and malignant pheochromocytoma. Exp Clin Endocrinol Diabetes 115: 155–159, 2007CrossRefPubMedGoogle Scholar
  18. 18.
    Bjorklund P, Pacak K, Crona J: Precision medicine in pheochromocytoma and paraganglioma: current and future concepts. J Intern Med 280: 559–573, 2016CrossRefPubMedGoogle Scholar
  19. 19.
    Feng F, Zhu Y, Wang X, et al.: Predictive factors for malignant pheochromocytoma: analysis of 136 patients. J Urol 185: 1583–1590, 2011CrossRefPubMedGoogle Scholar
  20. 20.
    Mannelli M, Castellano M, Schiavi F, et al.: Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab 94: 1541–1547, 2009CrossRefPubMedGoogle Scholar
  21. 21.
    Favier J, Amar L, Gimenez-Roqueplo AP: Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat Rev Endocrinol 11: 101–111, 2015CrossRefPubMedGoogle Scholar
  22. 22.
    Gimenez-Roqueplo AP, Burnichon N, Amar L, Favier J, Jeunemaitre X, Plouin PF: Recent advances in the genetics of phaeochromocytoma and functional paraganglioma. Clin Exp Pharmacol Physiol 35: 376–379, 2008CrossRefPubMedGoogle Scholar
  23. 23.
    Tischler AS, de Krijger RR: 15 years of paraganglioma: pathology of pheochromocytoma and paraganglioma. Endocr Relat Cancer 22: T123–T133, 2015CrossRefPubMedGoogle Scholar
  24. 24.
    Kimura N, Watanabe T, Noshiro T, Shizawa S, Miura Y: Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocr Pathol 16: 23–32, 2005CrossRefPubMedGoogle Scholar
  25. 25.
    Eisenhofer G, Tischler AS: Neuroendocrine cancer. Closing the GAPP on predicting metastases. Nat Rev Endocrinol 10: 315–316, 2014CrossRefPubMedGoogle Scholar
  26. 26.
    Suh I, Shibru D, Eisenhofer G, et al.: Candidate genes associated with malignant pheochromocytomas by genome-wide expression profiling. Ann Surg 250: 983–990, 2009CrossRefPubMedGoogle Scholar
  27. 27.
    Nolting S, Grossman AB: Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies. Endocr Pathol 23: 21–33, 2012CrossRefPubMedGoogle Scholar
  28. 28.
    Burnichon N, Vescovo L, Amar L, et al.: Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet 20: 3974–3985, 2011CrossRefPubMedGoogle Scholar
  29. 29.
    Santarpia L, Habra MA, Jimenez C: Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies. Horm Metab Res 41: 680–686, 2009CrossRefPubMedGoogle Scholar
  30. 30.
    Amar L, Bertherat J, Baudin E, et al.: Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 23: 8812–8818, 2005CrossRefPubMedGoogle Scholar
  31. 31.
    Jafri M, Maher ER: The genetics of phaeochromocytoma: using clinical features to guide genetic testing. Eur J Endocrinol 166: 151–158, 2012CrossRefPubMedGoogle Scholar
  32. 32.
    Burnichon N, Buffet A, Gimenez-Roqueplo AP: Pheochromocytoma and paraganglioma: molecular testing and personalized medicine. Curr Opin Oncol 28: 5–10, 2016CrossRefPubMedGoogle Scholar
  33. 33.
    Conzo G, Pasquali D, Colantuoni V, et al.: Current concepts of pheochromocytoma. Int J Surg 12: 469–474, 2014CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Department of SurgeryHallym University Sacred Heart HospitalAnyang-siSouth Korea
  2. 2.Department of PathologyHallym University Sacred Heart HospitalAnyangSouth Korea
  3. 3.Department of PathologySeoul National University Bundang HospitalSeongnamSouth Korea

Personalised recommendations